[A15-01] Nintedanib - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Last updated 01.04.2015
Project no.:
A15-01
Commission:
Commission awarded on 02.01.2015 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-36 | Nintedanib (idiopathic pulmonary fibrosis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| G15-03 | Nintedanib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment) | Commission completed |
| A20-70 | Nintedanib (systemic sclerosis associated interstitial lung disease in adults) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-71 | Nintedanib (interstitial lung disease) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2015-06-18 A G-BA decision was published.